Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 2/20 | 0.60 |
| ▸ | P2RY4 | P51582 | 2/20 | 0.60 |
| ▸ | TGM2 | P21980 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.56 |
| ▸ | KRAS | P01116 | 2/20 | 0.55 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.54 |
| ▸ | NT5E | P21589 | 1/20 | 0.53 |
| ▸ | POLG | P54098 | 1/20 | 0.52 |
| ▸ | PNP | P00491 | 1/20 | 0.51 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.49 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.49 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.49 |
| ▸ | P2RY1 | P47900 | 2/20 | 0.49 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.49 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.49 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.49 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.48 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.48 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Inx-09114 SCHEMBL10819844 | 1.00 | P2RY2 (0.60) | P2RY2P2RY4TGM2POLBFUT5 | |
| Inx-09114 SCHEMBL21006183 | 1.00 | P2RY2 (0.60) | P2RY2P2RY4TGM2POLBFUT5 | |
| Inx-09114 SCHEMBL13522450 | 1.00 | P2RY2 (0.60) | P2RY2P2RY4TGM2POLBFUT5 | |
| Inx-09114 SCHEMBL14946248 | 1.00 | P2RY2 (0.60) | P2RY2P2RY4TGM2POLBFUT5 | |
| Inx-09114 SCHEMBL14853807 | 1.00 | P2RY2 (0.60) | P2RY2P2RY4TGM2POLBFUT5 | |
| Inx-09114 SCHEMBL14929056 | 1.00 | P2RY2 (0.60) | P2RY2P2RY4TGM2POLBFUT5 | |
| Inx-09114 SCHEMBL23319265 | 1.00 | P2RY2 (0.60) | P2RY2P2RY4TGM2POLBFUT5 | |
| Inx-09114 SCHEMBL21007234 | 1.00 | P2RY2 (0.60) | P2RY2P2RY4TGM2POLBFUT5 | |
| SCHEMBL13522449 | 0.99 | TGM2 (0.59) | P2RY2P2RY4TGM2POLBFUT5 | |
| SCHEMBL1576874 | 0.99 | TGM2 (0.59) | P2RY2P2RY4TGM2POLBFUT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4531842-A2 | DOSAGE REGIMENS FOR TREATMENT OF DENGUE INFECTION | ATEA Pharmaceuticals, Inc. (US) | 2025-04-09 | — | — | EP | disclosed |
| US-20250082656-A1 | DOSAGE REGIMENS FOR TREATMENT OF DENGUE INFECTION | Atea Pharmaceuticals, Inc. (US) | 2025-03-13 | — | — | US | disclosed |
| CN-119255797-A | Dosing regimen for treating dengue infection | 阿堤亚制药公司 | 2025-01-03 | — | — | CN | disclosed |
| WO-2023230348-A2 | DOSAGE REGIMENS FOR TREATMENT OF DENGUE INFECTION | Atea Pharmaceuticals, Inc. (US) | 2023-11-30 | — | — | WO | disclosed |
| US-20230364121-A1 | NIRAN INTERFERING DRUGS FOR SARS-COV-2 MUTANT THERAPY | Atea Pharmaceuticals, Inc. (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230364121-A1 | NIRAN INTERFERING DRUGS FOR SARS-COV-2 MUTANT THERAPY | Atea Pharmaceuticals, Inc. (US) | 2023-11-16 | — | — | US | disclosed |
| EP-4172364-A1 | CATALYTICALLY CONTROLLED SEQUENCING BY SYNTHESIS TO PRODUCE SCARLESS DNA | Illumina, Inc. (US) | 2023-05-03 | — | — | EP | disclosed |
| CN-115997033-A | Catalytic control sequencing by synthetic generation of traceless DNA | 伊鲁米纳公司 | 2023-04-21 | — | — | CN | disclosed |
| WO-2022108701-A1 | COMPOSITIONS AND METHODS FOR SEQUENCING USING FLUOROPHORES AND QUENCHERS OR DONORS | ILLUMINA, INC. (US) | 2022-05-27 | — | — | WO | disclosed |
| US-20220162680-A1 | COMPOSITIONS AND METHODS FOR SEQUENCING USING FLUOROPHORES AND QUENCHERS OR DONORS | ILLUMINA, INC. (US) | 2022-05-26 | — | — | US | disclosed |
| US-20100003217-A1 | Compounds and Pharmaceutical Compositions for the Treatment of Viral Infections | CRETTON-SCOTT ERIKA | 2010-01-07 | — | — | US | disclosed |
| US-20090118223-A1 | Novel 2'-c-methyl and 4'c-methyl nucleoside derivatives | MERCK SHARP & DOHME CORP. | 2009-05-07 | — | — | US | disclosed |
| EP-1915053-A2 | NOVEL 2'-C-METHYL AND 4'-C-METHYL NUCLEOSIDE DERIVATIVES | Merck & Co., Inc. (US) | 2008-04-30 | — | — | EP | disclosed |
| EP-1905778-A2 | Novel 2'-C-methyl nucleoside derivatives | Metabasis Therapeutics, Inc. (US) | 2008-04-02 | — | — | EP | disclosed |
| US-20070179114-A1 | Novel 2'-C methyl nucleoside derivatives | METABASIS THERAPEUTICS, INC. (US) | 2007-08-02 | — | — | US | disclosed |
| US-20070042989-A1 | Novel 2'-C-methyl nucleoside derivatives | METABASIS THERAPEUTICS, INC. (US) | 2007-02-22 | — | — | US | disclosed |
| WO-2007022073-A2 | NOVEL 2'-C-METHYL AND 4'-C-METHYL NUCLEOSIDE DERIVATIVES | MERCK & CO., INC. (US) | 2007-02-22 | — | — | WO | disclosed |
| EP-1720556-A2 | NOVEL 2'-C-METHYL NUCLEOSIDE DERIVATIVES | Merck & Co., Inc. (US) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005084192-A2 | NOVEL 2’-C-METHYL NUCLEOSIDE DERIVATIVES | MERCK & CO., INC. (US) | 2005-09-15 | — | — | WO | disclosed |
| US-20050182252-A1 | Hepatitis C viral infection; 2'-C-beta-methyl-7-deazaadenosine; trans-4-(aryl)-2-(4-nitrophenoxy)-2-oxo-1,3,2-dioxaphosphorinanes | METABASIS THERAPEUTICS, INC. | 2005-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100003217-A1 | Compounds and Pharmaceutical Compositions for the Treatment of Viral Infections | HAVCR2, PYGL, GOT1 | P2RY2 2250/4885P2RY4 1225/4885TGM2 397/4885 |
| US-20230364121-A1 | NIRAN INTERFERING DRUGS FOR SARS-COV-2 MUTANT THERAPY | NSUN2, ACE2, PNP | P2RY2 1640/4885P2RY4 1725/4885TGM2 394/4885 |
| US-20050182252-A1 | Hepatitis C viral infection; 2'-C-beta-methyl-7-deazaadenosine; trans-4-(aryl)-2-(4-nitrophenoxy)-2-oxo-1,3,2-dioxaphosphorinanes | MTAP, NT5C3B, ADAR | P2RY2 637/4885P2RY4 472/4885TGM2 2235/4885 |
| US-20070042989-A1 | Novel 2'-C-methyl nucleoside derivatives | NSUN2, NT5C3B, MTAP | P2RY2 1553/4885P2RY4 1930/4885TGM2 1465/4885 |
| US-20250082656-A1 | DOSAGE REGIMENS FOR TREATMENT OF DENGUE INFECTION | FCGR3B, HAVCR2, FCGR2A | P2RY2 1380/4885P2RY4 510/4885TGM2 4064/4885 |
| US-20090118223-A1 | Novel 2'-c-methyl and 4'c-methyl nucleoside derivatives | MTAP, NT5C3B, NSUN2 | P2RY2 679/4885P2RY4 413/4885TGM2 1500/4885 |
| US-20070179114-A1 | Novel 2'-C methyl nucleoside derivatives | NSUN2, NT5C3B, MTAP | P2RY2 1647/4885P2RY4 2297/4885TGM2 1522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.